Pharsight

Dhivy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439613 AVION PHARMS Levodopa fractionated dose composition and use
Mar, 2039

(15 years from now)

US11033521 AVION PHARMS Levodopa fractionated dose composition and use
Mar, 2039

(15 years from now)

Dhivy is owned by Avion Pharms.

Dhivy contains Carbidopa; Levodopa.

Dhivy has a total of 2 drug patents out of which 0 drug patents have expired.

Dhivy was authorised for market use on 12 November, 2021.

Dhivy is available in tablet;oral dosage forms.

Dhivy can be used as treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication, treatment of parkinson's disease; method of treating parkinson's disease by orally administering segments of a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, each segment having carbidopa—6.25 mg/levodopa—25 mg; method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg.

The generics of Dhivy are possible to be released after 28 March, 2039.

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Market Authorisation Date: 12 November, 2021

Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease;...

Dosage: TABLET;ORAL

More Information on Dosage

DHIVY family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic